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Objectives: Accurate diagnosis of salivary gland neoplasms (SGN) in many centers in 
Africa is limited by poor diagnostic resources and ancillary services. Hence, we have 
carried out a multicenter epidemiological study to understand the true burden of 
SGN in Nigeria.
Method: In this descriptive cross‐sectional study, we have deployed resources avail‐
able to members of the African Oral Pathology Consortium (AOPRC) to examine the 
burden of salivary gland lesions in Nigeria, using a multicenter approach. Data from 
seven major tertiary health institutions in northern, western, and southern Nigeria 
were generated using a standardized data extraction format and analyzed using the 
Epi‐info software (Version 7.0, Atlanta, USA).
Result: Of the 497 cases examined across the seven centers, we observed that SGN 
occurred more in females than males. Overall, pleomorphic salivary adenoma (PA) 
was found to be the most common. PA was found to be the commonest benign SGN 
while adenocystic carcinoma (ADCC) was the commonest malignant SGN. Regional 
variations were observed for age group, diagnosis, and gender distribution. Significant 
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1  | INTRODUC TION
Salivary gland neoplasms (SGN) are tumors that form within the tis‐
sues of major or minor salivary glands. SGN are an uncommon het‐
erogeneous group of lesions, with varying biological features, arising 
within tissue of the major or minor salivary glands (El‐Naggar, Chan, 
Grandis, Takata, & Slootweg, 2017). There is a dearth of information 
on the total incidence of SGN in various regions due to underreport‐
ing of cases in national cancer registries (Valstar et al., 2017).
The global annual incidence of SGN is 0.4–13.5 cases per 
100,000 individuals and has a prevalence of 3%–6% of all head and 
neck tumors depending on the study (Tian, Li, Wang, Hu, & Li, 2010).
There are up to 35 different lesions categorized by WHO as 
SGN with vast majority (ca. 65%–75%) of them designated as benign 
neoplasm (El‐Naggar et al., 2017; Mehanna, McQueen, Robinson, 
& Paleri, 2012). Salivary gland carcinoma (SGC), although less com‐
mon, represents at least 24 different histological subtypes, making it 
a challenging group of lesions to study and develop treatment stan‐
dards for (Leivo, 2006).
Most publications have indicated a slight female predominance; 
however, the sex ratio varies in different tumor types (de Oliveira et 
al., 2009; Li, Li, Wen, Liu, & Zhao, 2008).
No racial differences have been clearly defined; however, Yaor 
(2010) reported different patterns of salivary gland tumors between 
Africa and the western regions of the World.
There is a wide age distribution, with a peak incidence in the fifth 
decade (Barnes, 2009).
The etiology of SGN is largely unknown (Boukheris, Curtis, 
Land, & Dores, 2009). Unlike oral cancers, which are largely asso‐
ciated with tobacco usage and alcohol consumption, studies have 
shown that there is no independent effect of smoking and drinking 
on the risk of SGC (Li et al., 2017). Exposure to ionizing radiation 
is associated with an increased risk of SGN (El‐Naggar et al., 2017; 
Preston‐Martin & White, 1990). SGCs have been found more associ‐
ated with alterations of the immune status as found in HIV/AIDS in‐
fection (Ebrahim, Singh, & Ramklass, 2014) and Sjogren’s syndrome 
(Fragkioudaki, Mavragani, & Moutsopoulos, 2016). Also, the role of 
genetic and viral etiology is yet to be fully investigated (Yin & Ha, 
2016).
Tumors can occur in both the major and the minor salivary 
glands, and most series published in the literature showed that SGC 
is commoner in major salivary glands, especially the parotid (20%–
25%) (Arshad, 1998). This rises to 40% for the submandibular glands, 
and more than 90% of sublingual gland tumors are malignant and 
almost always carcinomas (Arshad, 1998; Loyola, Araujo, Sousa, & 
Araujo, 1995). When they affect minor salivary glands, the palate is 
the most affected site (Speight & Barrett, 2002). Although discrepan‐
cies exist in the literature with regard to the commonest SGC, most 
studies have shown mucoepidermoid carcinoma, adenoid cystic car‐
cinoma, and carcinoma ex pleomorphic adenoma as the commonest 
histologic types (Eveson & Cawson, 1985; Lima, Soares, Amorim, & 
Freitas Rde, 2005; Ribeiro Kde, Kowalski, Saba, & Camargo, 2002).
Salivary gland tumors typically present as long‐standing or re‐
cently developing lump in the affected gland and may lead to xero‐
stomia as a result of blockage of the salivary duct. In the early stages, 
it is often difficult to clinically delineate benign from malignant le‐
sions. However, signs such as facial nerve damage/palsy, pain, and 
paresthesia are commoner in malignant salivary gland lesions; so is 
fixation or tethering of the swelling to the overlying skin, induration, 
and ulceration of the mucosa (Mehanna et al., 2012).
Albeit sometimes inconclusive, diagnostic techniques such as 
fine needle aspiration cytology (FNAC) have been used for SGCs 
(Thoeny, 2007). FNAC can be subject to sampling bias, particularly 
if the tumor is in the deep lobe of the parotid (Thoeny, 2007). Not 
least, some authors have reported cases of tumor capsule seed‐
ing following FNAC procedures (Freling, Crippa, & Maroldi, 2016; 
Haldar, Sinnott, Tekeli, Turner, & Howlett, 2016; Sood, McGurk, & 
Vaz, 2016). Other diagnostic imaging techniques such as magnetic 
resonance imaging (MRI), computed tomography (CT), and ultraso‐
nography (US) have been found highly beneficial in the diagnosis 
of SGC tumor location, extent, and the presence of perineural in‐
vasion (Haldar et al., 2016; Rudack, Jörg, Kloska, Stoll, & Thiede, 
2007). Although revision of the current preoperative diagnostic 
approaches is deemed necessary, as neither CT, US nor MRI was 
found to be superior in the diagnostic work‐up of SGCs (Rudack et 
al., 2007).
The histogenesis of SGC may be from acinar cell, stem cells, or 
reserve cells in the duct system (Chaudhry et al., 1989). This histo‐
logic diversity is further complicated by the presence of extracellular 
matrix component which is believed to be secreted by myoepithelial 
cells (Marx & Stern, 2003). It is more likely that there is involvement 
of one cell type in SGC histogenesis (Leivo, 2006).
statistical differences were found between males and females for malignant SGNs 
(p‐value=0.037).
Conclusion: We found regional variation in the pattern of distribution of SGN in 
Nigeria. This is the largest multicenter study of SGN in Nigeria, and our findings are 
robust and representative of the epidemiology of this neoplasm in Nigeria.
K E Y W O R D S
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Consensus is that, the global prevalence of SGN is not well estab‐
lished (Pinkston & Cole, 1999), and there is a need for more qualita‐
tive data to establish its pattern in various regions of the world. Even 
though several papers have been published on salivary gland tumors 
in sub‐Saharan Africa (particularly from Nigeria) (Fomete, Adebayo, 
& Ononiwu, 2015; Ladeinde, Adeyemo, Ogunlewe, Ajayi, & Omitola, 
2007; Otoh, Johnson, Olasoji, Danfillo, & Adeleke, 2005), most are 
culled from single institutions. One important limitation of single 
center studies, inter alia, is the fact that it obscures the complete 
picture of the disease entity being investigated since data obtained 
are not representative of the entire population. In order to under‐
stand the clinical features and design novel treatment modalities 
that improve both diagnostic and treatment outcomes, it is neces‐
sary to evaluate the pattern and distribution of these heterogeneous 
tumors. This study was a collaboration of data accessed from seven 
different tertiary medical institutions across northern and southern 
Nigeria,involving members of the African Oral Pathology Research 
Consortium (AOPRC). A multicenter study of this caliber allowed 
us to investigate regional variations in SGN among people from the 
most populous nation in Africa.
2  | MATERIAL S AND METHODS
2.1 | AOPRC participants
The African Oral Pathology Research Consortium (AOPRC) was 
inaugurated during the 1st regional congress of the International 
Association of Oral Pathologists (IAOP), which took place in Lagos, 
Nigeria in September 2015. The objectives for creating AOPRC in‐
clude the following: advancing multicenter collaborative oral pathol‐
ogy research; exchange of skills and expertise; and strengthening 
ties between oral pathologists across Africa and further afield, inter 
alia. The AOPRC currently has members based at the University 
of Ibadan, Nigeria; University of Port Harcourt, Nigeria; University 
of Lagos, Nigeria; Obafemi Awolowo University, Ile‐Ife, Nigeria; 
Federal Medical Centre, Asaba, Nigeria; University of Cape Town, 
South Africa; University of the Western Cape at Tygerberg Hospital, 
South Africa; and University of Iowa, USA. A multicenter study on 
the burden of salivary gland tumors in Nigeria was carried out due to 
the collaborative efforts of the AOPRC.
2.2 | Data source
Deidentified secondary archived data from seven major tertiary health 
institutions in southwest, northwest, and south–south regions of Nigeria 
were used in this study. Records of all patients with salivary glands tu‐
mors (benign and malignant) at the Lagos University Teaching Hospital 
(LUTH), Lagos State University Teaching Hospital (LASUTH), University 
College Hospital, Ibadan (UCH), Obafemi Awolowo University Teaching 
Hospital, Ile‐Ife (OAUTHC) all in South‐West Nigeria; University of 
Port Harcourt Teaching Hospital (UPTH), University of Benin Teaching 
Hospital (UBTH) both in South‐South Nigeria; and Usmanu Danfodiyo 
University Teaching Hospital, Sokoto (UDUTH) which is in northwest 
Nigeria were extracted from 2007 to 2016 (10 years), using a standard‐
ized data extraction form. Demographic, clinical, and histopathological 
data, such as age distribution, site, gender distribution, and histological 
diagnosis, inter alia, were extracted from the records.
2.3 | Case selection and exclusion criteria
Cases with inadequate clinical and histopathological information 
were excluded from the study. A total of 497 cases of salivary gland 
tumors were included from the participating centers. The SGN were 
categorized by histological type, site of primary tumor, age, and gen‐
der distribution.
TA B L E  1   Distribution of tumor by age groups
Age group 
(years) Benign (%) Malignant (%) Total (%)
<10 5 (2.6%) 4 (1.3%) 9 (1.8%)
10 to 19 19 (10.1%) 11 (3.6%) 30 (6.0%)
20 to 29 40 (21.2%) 28 (9.1%) 68 (13.7%)
30 to 39 44 (23.2%) 59 (19.2%) 103 (20.7%)
40 to 49 39 (20.6%) 64 (20.8%) 103 (20.7%)
50 to 59 24 (12.7%) 53 (17.2%) 77 (15.5%)
60 to 69 14 (7.4%) 51 (16.6%) 65 (13.1%)
70 to 79 2 (1.1%) 25 (8.1%) 27 (5.4%)
>80 2 (1.1%) 13 (4.2%) 15 (3.0%)
Total 189 (100.0) 308 (100.0%) 497 (100.0%)
TA B L E  2   Distribution of tumor diagnosis by gender
Diagnosis Male (%) Female (%)
ADCC 55 (28.6%) 87 (28.6%)
BCA 12 (6.3%) 7 (2.3%)
CA‐EX PA 12 (6.3%) 9 (3.0%)
Malignant myoepithelioma 3 (1.6%) 4 (1.3%)
MEC 42 (21.9%) 46 (15.1%)
Mucinous CA 1 (0.5%) 1 (0.3%)
Oncocytoma 0 (0.0%) 1 (0.3%)
PA 36 (18.8%) 128 (42.0%)
PCAC 2 (1.0%) 2 (1.0%)
PLGA 26 (13.5%) 16 (13.5%)
SDC 3 (1.6%) 3 (1.6%)
WT 0 (0.0%) 1 (0.0%)
Total 192 (100.0%) 305 (100.0%)
Note. ADCC, Adenoid cystic carcinoma; BCA, Basal cell adenoma; 
CAexPA, carcinoma ex pleomorphic adenoma; MEC, Mucoepidermoid 
carcinoma; PA, Pleomorphic adenoma; PCAC, Papillary 
Cystadenocarcinoma; PLGA, Polymorphous low‐grade adenocarcinoma; 
SDC, Salivary ductal carcinoma; WT, Warthin tumor.
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2.4 | Data analysis
Data from the selected 497 cases were collated and processed using 
the Epi‐info software (Version 7.0, Atlanta, GA, USA). Categorical vari‐
ables were analyzed as frequencies and percentages, while quan‐
titative variables were summarized as means. Differences in mean 
were compared with Student’s t test and ANOVA while differences 




There was a statistically significant difference between the mean 
ages of patients with benign and malignant SGN (p < 0.001). The 
mean age of all patients with benign lesions was 37.1 with a range 
of 6–100 years, while the mean age of those with malignant lesions 
was 48.9, with a range of 4–86 years. Of the benign SGN, data from 
UPTH had the highest mean age of 50.6 years while OAUTHC pre‐
sented with the highest mean age of 53.6 for malignant lesions.
The peak age incidence of SGN in this study was bimodal be‐
tween fourth and fifth decades, seen in 103 (20.7%) cases (Table 1). 
The highest frequency of 44 (23.2%) for benign SGN was observed 
in the fourth decade while the highest frequency 64 (20.8%) for 
malignant SGN was observed within the fifth decade and was sta‐
tistically significant. Data from UCH and LUTH showed the highest 
frequency of malignant SGN, each with 86 cases, while the least was 
observed in LASUCOM with 17. UDUTH had the highest frequency 
of benign SGN (with 45 cases), while UPTH presented the least num‐
ber (5) of benign SGN.
3.2 | Distribution of tumor diagnosis by gender
There were 305 (62.0%) females and 192 (38.0%) males with a M:F of 
1:1.6. Notably, in all the centers studied, both benign and malignant 
salivary gland tumors were more prevalent in females (p < 0.050). 
Both the commonest benign (pleomorphic adenoma) and the malig‐
nant (adenoid cystic carcinoma) lesions were most commonly seen in 
females. While this observation was statistically significant for ade‐
nocystic carcinoma (p < 0.050), it was not significant for pleomorphic 
adenoma (Table 2). Male predominance was found in patients with 
basal cell adenoma, carcinoma ex pleomorphic adenoma, and poly‐
morphous low‐grade adenocarcinoma. Equal gender distribution was, 
however, observed for mucoepidermoid carcinoma (MEC), salivary 
ductal carcinoma (SDC), and papillary cystadenocarcinoma (PCAC).




(p‐value)Frequency Percent Frequency Percent Frequency Percent
Major
Parotid 43 13.96% 38 20.11% 81 16% 3.24 (0.0717)**
Submandibular 21 6.82% 23 12.17% 44 9% 1.45 (0.3254)**
Sublingual 8 2.60% 0 0.00% 8 2% 4.98 (0.0255)*
Minor
Antrum 46 14.94% 2 1.06% 48 10% 25.85 (<0.0001)*
Buccal Mucosa 16 5.19% 7 3.70% 23 5% 0.55 (0.4564)**
Cheek 23 7.47% 44 23.28% 67 13% 25.11 (<0.0001)*
Gingiva 2 0.65% 2 1.06% 4 1% 0.24 (0.6204)**
Lower lip 5 1.62% 5 2.65% 10 2% 0.62 (0.4308)**
Mandible 26 8.44% 2 1.06% 28 6% 0.39 (0.5320)**
Maxilla 7 2.27% 1 0.53% 8 2% 2.24 (0.1337)**
Neck 1 0.32% 0 0.00% 1 0% 0.61 (0.4329)**
Orbito‐zygomatic 1 0.32% 0 0.00% 1 0% 0.61 (0.4329)**
Palate 94 30.52% 47 24.87% 141 28% 1.73 (0.1897)**
Preauricular 
region
1 0.32% 0 0.00% 1 0% 0.61 (0.4329)**
Retromolar 4 1.30% 2 1.06% 6 1% 0.05 (0.8116)**
Tongue 5 1.62% 0 0.00% 5 1% 3.09 (0.0783)**
Upper lip 3 0.97% 6 3.17% 9 2% 3.18 (0.0740)**
NA 2 0.65% 10 5.29% 12 2% 10.71 (0.0010)*
Total 308 100.00% 189 100.00% 497 100%
*Difference between both groups is statistically significant. **Difference between both groups is not statistically significant. 
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3.3 | Distribution of tumor diagnosis by site
Most of the SGN originated from the minor salivary gland (n = 351, 
70.6%). The palate (n = 141, 28.0%) was the commonest site for all 
SGN, followed by the parotid (n = 81, 16.0%) and the cheek (n = 67, 
13.0%). Similarly, the palate was observed to have the highest 
number of both malignant (n = 94, 30.5%) and benign (n = 47, 
24.9%) lesions; however, there was no statistical significant dif‐
ference observed. Benign lesions of the cheek were statistically 
significantly more observed than malignant lesion from the same 
site (Table 3; p < 0.001). Antral lesions were mostly malignant 
(n = 46/48, p < 0.001), as were all lesions from the sublingual gland 
(n = 8/8, p‐value =0.025). In the major glands, malignant lesions 
(n = 72/133, 54.0%) were found to be more than benign lesions 
(61/133, 46.0%).
3.4 | Distribution of tumors by center
The highest frequency of occurrence of SGN was observed in UCH 
(n = 116, 23.3%), which was followed by LUTH (n = 111, 22.3%). The 
lowest frequency was seen in OAUTHC (n = 34, 6.8%). Of the total 
of 497 SGN seen over the study period, malignant SGN constituted 
308 (62.0%) while the benign lesion was 189 (38.0%) (Table 4).
3.5 | Regional distribution of SGN diagnosis 
by center
Overall, of all recorded tumors per center, adenocystic carcinoma 
(ADCC) was found to have the highest frequency in LUTH (47), UCH 
(44), and OAUTHC (11), all in southwestern Nigeria. Among all be‐
nign lesions, pleomorphic adenoma (PA) was the most common in 
all centers, with highest frequencies in UDUTH (42) and UBTH (36).
3.6 | SGN distribution according to tumor diagnosis
Overall, PA was the most frequent (n = 164, 33.0%), closely followed 
by ADCC (n = 142, 28.6%) and MEC (n = 88, 17.7%) (Table 5). The 
least common SGN was WT and oncocytoma both having a fre‐
quency of 1 each.
4  | DISCUSSION
Salivary gland tumors often pose diagnostic challenges (Peravali, Bhat, 
Upadya, Agarwal, & Naag, 2015; Tyagi & Dey, 2015), even in the most 
equipped centers in the world. This is more so in the African continent, 
where diagnostic resources are limited and need to be managed judi‐
ciously (Adeola, Soyele, Adefuye, Jimoh, & Butali, 2017). To our knowl‐
edge, this is the largest multicenter study of SGN in Africa.
We observed mean ages of diagnosis for benign tumors to be 37.1 
(±15.4) years and malignant tumors to be 48.9 (±17.3) years. The mean 
age of diagnosis for malignant tumors in our study is similar to that 
reported for both benign and malignant tumors in Tanzania (Masanja, 
Kalyanyama, & Simon, 2003) and Brazil (Takahama Junior, Almeida, & 
Kowalski, 2009). Our observed mean ages of diagnosis were, however, 
lower than ages reported in a study by SatkoStanko & Longauerova, 
2000 in Slovakia; where the mean ages reported for benign and ma‐
lignant tumor were 46 and 53 years, respectively (Satko et al., 2000). 
Furthermore, the mean ages of diagnosis in our study are also lower 
than mean ages reported by Araya, Martinez, Niklander, Marshall, & 
Esguep, 2015 in Chile (mean age for benign and malignant tumors were 
53.3 ± 19.09 and 60.9 ± 26.6) (Araya et al., 2015), as well as ages re‐
ported by Tartaglione et al., 2015 in Italy (mean age for benign tumors, 
it was 50.7 years and malignant tumors was 65.2 years) (Tartaglione et 
al., 2015). The similarity in mean ages to the Tanzanian and Brazilian 
study could be due to the similar African genomic architecture in these 
populations which is different from the other populations.
TA B L E  4   Distribution of tumor types in the different centers
Location Benign (%) Malignant (%)
Chi‐squared test 
(p‐value)
UCH 30 (15.9%) 86 (27.9%) 10.05 (0.0015)a
LUTH 25 (13.2%) 86 (27.9%) 14.17 (0.0002)a
UDUTH 46 (24.3%) 19 (6.2%) 33.10 (<0.0001)a
OAUTHC 13 (6.9%) 21 (6.8%) 0.01 (0.9545)a
UPTH 5 (2.6%) 33 (10.7%) 10.61 (0.0011)a
UBTH 39 (20.6%) 46 (14.9%) 2.86 (0.0904)b
LASUCOM 31 (16.4%) 17 (5.5%) 16.25 (<0.0001)a
Total 189 (100.0%) 308 (100.0%)
aDifference between the groups is statistically significant (p < 0.05). 
bDifference between the groups is not statistically significant (p > 0.05). 
TA B L E  5   Distribution of tumor diagnosis
Diagnosis Frequency (n) Percent (%)
ADCC 142 28.6%
BCA 19 3.8%
Ca‐Ex PA 21 4.2%
Malignant myoepithelioma 7 1.4%
MEC 88 17.7%








Note. ADCC, Adenoid cystic carcinoma; BCA, Basal cell adenoma; 
CAexPA, carcinoma ex pleomorphic adenoma; MEC, Mucoepidermoid 
carcinoma; PA, Pleomorphic adenoma; PCAC, Papillary 
Cystadenocarcinoma; PLGA, Polymorphous low‐grade adenocarcinoma; 
SDC, Salivary ductal carcinoma; WT, Warthin tumor.
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Similar age trends were observed for benign and malignant SGN 
with peak incidences at 44 and 59 years, respectively. The higher 
incidence and age in the malignant group is consistent with what 
has been reported in most studies (Araya et al., 2015; Masanja et al., 
2003; Satko et al., 2000; Takahama Junior et al., 2009; Tartaglione 
et al., 2015).
However, the decline in number of benign and malignant cases 
after ages 30–39 and 40–49 years of age, respectively, may reflect 
an increase in mortality or comorbidity in subsequent ages, limiting 
the number of new cases recorded at the hospital.
The histopathological pattern of salivary gland tumors has been 
reported by several authors from different geopolitical zones in 
Nigeria, showing diverse distribution patterns (Fomete et al., 2015; 
Jude & Olu‐Eddo, 2014; Ladeinde et al., 2007; Otoh et al., 2005). 
This study found more malignant salivary gland tumors than benign 
tumors which are similar to reports by Fomete et al (2015), and 
Aliyu et al. (2016) but is in contrast to the report by Shishegar et al 
(2011) and Jude and Olu‐Eddo (2014), who found more benign sal‐
ivary gland tumors. These variations in benign and malignant SGN 
incidence may reflect regional differences and highlight the need 
for multicenter collaborations to get a truly representative disease 
burden. As reported by several studies (Bobati, Patil, & Dombale, 
2017; Otoh et al., 2005; Sando, Fokouo, Mebada, Djomou, & A ND 
and Oyono JL, 2016; Shishegar et al., 2011), pleomorphic adenoma 
was the most common salivary gland tumor overall and the most 
common benign tumor, similar to the findings from our study. In 
a study in north central Nigeria (Fomete et al., 2015), in general, 
ADCC was reported as the most common salivary gland tumor; al‐
beit second overall in our study. Sando et al (2016) in Cameroon, 
Bobati et al (2017) in India and Lima et al (2005) in Brazil found 
ADCC as the most common malignant salivary gland tumor in their 
case series. Among the malignant tumors, however, some authors 
(including Nigerians) have reported mucoepidermoid carcinoma, 
as the most frequent tumor (Pinkston & Cole, 1999; Sun, Curtis, 
Melbye, & Goedert, 1999). These findings show a variation in the 
prevalence of the histological types which may be attributed to the 
type of predisposing etiological factors in the different geographic 
zones. Further studies on these regional predisposing factors may 
elicit the reasons for the variation in histopathological patterns of 
presentation.
This study also showed a wide anatomic distribution of SGN, 
including difference between centers investigated. Neoplasms of 
minor salivary glands were more common than those from major sal‐
ivary glands. This is similar to the study of Ladeinde et al. (2007) but 
differs from several other studies which reported more neoplasms of 
the major than the minor glands (Ito, Ito, Vargas, Almeida, & Lopes, 
2005; Lawal, Adisa, Kolude, Adeyemi, & Olajide, 2013; Otoh et al., 
2005). The palate was the most commonly affected site followed by 
the parotid gland in our study. This contrasts with many studies that 
observed the parotid gland as the most commonly affected primary 
site (Ito et al., 2005; Tian et al., 2010). The reason for this discrep‐
ancy is not clear, but it suffices to know that the pattern may be 
related to data available to the researchers.
The highest prevalence in ADCC was seen in LUTH and UCH in 
the southwest zone. This finding is consistent with report from a 
previous single‐center study by Ladeinde et al (2007) and Lawal et 
al (2013), respectively, who in their studies observed ADCC as the 
most common malignant salivary gland tumors in their centers. The 
low frequency of ADCC in UPTH, south–south in comparison with 
LUTH and UCH may be due to the low number of cases seen there, 
and the fact that LUTH and UCH are older, and more well‐established 
centers. However, UPTH and UDUTH observed a high frequency of 
MEC which concurs with reports by Sun et al (1999) and Pinkston 
and Cole (Pinkston & Cole, 1999). This alludes to the variation in 
the occurrence of salivary gland tumors in the different geopolitical 
zones (Sando et al., 2016). The single most common lesion (benign 
and malignant) in this study is the pleomorphic adenoma, and this 
is similar to the observation of Ladeinde et al (2007), Oti, Donkor, 
Obiri‐Yeboah, and Afriyie‐Owusu (2013), Bahra, Butt, Dimba, and 
Macigo (2012) but contrasts the observations of Aliyu et al. (2016) 
and Omitola, Iyogun, and Osagbemiro (2016), in which squamous cell 
carcinoma and mucoepidermoid carcinoma were the most common 
lesions, respectively. Similar to the observation of Ladeinde et al. 
(2007), Oti et al. (2013), and Bahra et al. (2012), adenocytic carci‐
noma was the most common malignant lesion in this study.
Among the benign lesions, PA was the most prevalent tumor in 
our study, which is similar to earlier reports (Bobati et al., 2017; Otoh 
et al., 2005; Sando et al., 2016; Shishegar et al., 2011). The highest oc‐
currence of PA was seen in UDUTH, which is in northwestern Nigeria, 
followed by UBTH Benin, which is in the south–south geopolitical 
zone. A previous study in UDUTH by Aliyu et al. (2016) reported 
more malignant tumors. Warthins tumor and oncocytoma were of a 
low prevalence in this study which agrees with findings from previous 
studies on the low frequency of occurrence of these tumors (Aliyu et 
al., 2016; Fomete et al., 2015; Sando et al., 2016). As found in other 
studies (Bahra et al., 2012; Jones, Craig, Speight, & Franklin, 2008; 
Omitola et al., 2016), salivary gland lesions affected more females 
than males. This may be related to the general belief that females 
tend to seek health care more than males (Hunt, Adamson, Hewitt, 
& Nazareth, 2011); although male preponderance of SGNs has been 
reported as well (Ladeinde et al., 2007; Oti et al., 2013).
The prevalence of pleomorphic adenoma which is the commonest 
benign lesion and the commonest lesion overall in this study was sig‐
nificantly higher in females while carcinoma ex pleomorphic adenoma 
was significantly higher in males. The reason for this observation is not 
clear, but other studies have reported both similar (Aliyu et al., 2016; 
Bahra et al., 2012) and contrary findings (Oti et al., 2013). Ladeinde et al. 
(2007) reported equal prevalence in both sexes for ca ex pleomorphic 
adenoma. Variations in the incidences of carcinoma ex pleomorphic 
adenoma may be a reflection of the total number of cases accessible 
from individual centers, and warrants further research. Adenoid cystic 
carcinoma which is the most common malignant lesion in this study was 
also most prevalence in females. This observation is similar to the ob‐
servation of Ladeinde et al (2007), but contrary to the reports of most 
other researchers that have reported the prevalence of this lesion in 
males (Aliyu et al., 2016; Bahra et al., 2012; Oti et al., 2013).
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We present in this study, the largest multicenter evaluation of SGN 
on the African continent. Even though, up to 80% of the global 
cancer burden can be found in low‐ and middle‐income coun‐
tries (LMICs), it receives only 5% of the global cancer spending 
(Knaul, Atun, Farmer, & Frenk, 2013). As African oral pathologists, 
we recognize the importance of academic partnership and multi‐
center initiatives to improve our understanding of oral diseases 
within the African continent. Using this multicenter approach ef‐
fectively, we previously investigated the burden of oral cancer 
in southern and western Nigeria (Omitola et al., 2017). We have 
evaluated the clinic‐pathological characteristics of close to 500 
salivary gland lesions across seven tertiary centers in northern and 
southern Nigeria. Overall, we found pleomorphic adenoma to be 
the most common SGN. This was also true in the benign category. 
Adenocystic carcinoma was found to be the commonest malignant 
salivary gland neoplasm. Cystadenocarcinomas and oncocytomas 
were the least frequent in our study. Findings in this collaborative 
team research will help oral pathologists to understand areas in 
salivary gland neoplasia that require urgent research efforts on the 
African continent. Also, an equitable distribution of manpower, in‐
creased education and awareness of this salivary gland lesion in all 
the regions of Nigeria, will serve to promote early detection. This 
study also provides a foundation for further studies on etiology 
and prevention.
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